Majumder S, et al. - During this trial, experts attempted to compare the outcomes of patients with pancreaticobiliary immunoglobulin G4-related disease (IgG4-RD) treated with or without maintenance rituximab therapy. Rituximab maintenance therapy was discovered to prolong remission. Findings unveiled that relapses were uncommon among patients receiving maintenance therapy. Nevertheless, maintenance therapy could increase the risk of infection. It was also deduced that individuals with factors that predict relapse could serve as candidates for rituximab maintenance therapy.